Company Onyx Pharmaceuticals, Inc.
Equities
US6833991093
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Aug. 27 | Gilead Sciences, Inc. : Bradway's patient dealmaking brings Onyx to Amgen | RE |
Aug. 26 | Onyx Pharmaceuticals, Inc. : Onyx deal expected to give Amgen a big boost | RE |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 73,338,780 | 73,162,002 ( 99.76 %) | 0 | 99.76 % |
Sector
1st Jan change | Capi. | |
---|---|---|
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |
- Stock
- Equities
- Stock Onyx Pharmaceuticals, Inc. - Nasdaq
- Company Onyx Pharmaceuticals, Inc.